A Phase 4 interventional study of Pyridostigmine oral tablet and Placebo in Underactive Bladder, TURP(transurethral Resection of Prostate) and BPH (Benign Prostatic Hyperplasia), sponsored by Menoufia University. Completed at 1 site in Egypt. Open to male participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Menoufia University · Phase 4, Interventional, and Treatment
The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder
Underactive bladder is a decrease in detrusor contraction and/or shortening of the contraction time, resulting in an incomplete and/or prolongation of the bladder emptying within the normal time frame. Prolonged bladder outlet obstruction due to prostatic enlargment one of the main causes of bladder hypocontractility. To make a diagnosis, it is necessary to perform a pressure-flow study. Decrease in maximum urine flow rate related to bladder outlet obstruction or poor contractility can be distinguished by pressure-flow study.
parasympathomimetics (cholinergic receptor stimulating agents) could be beneficial for patients with underactive bladder. However, no systematic review with meta-analysis addressing potential benefits or adverse effects exists. Pyridostigmine is a medication used to treat myasthenia gravis and underactive bladder as well.
Patients with underactive bladder after transurethral resection of prostate may still complain of recurrent attacks of obstructive lower urinary tract symptoms.
31 studies on the registry are indexed under Urinary Bladder, Underactive; 6 are open to participants now.
This study's enrollment of 66 is close to the median of 66 across 21 interventional studies indexed under Urinary Bladder, Underactive.
Browse Urinary Bladder, Underactive studies →Menoufia University is the lead sponsor of 199 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
this group will receive pyridostigmine 60 mg twice daily.
Drug: Pyridostigmine oral tablet
This will receive placebo postoperatively.
Drug: Placebo
Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months
Placebo oral tablet, twice daily, for 3 months
Severity of lower urinary tract symptoms
Severity of lower urinary tract symptoms will be assessed by International Prostate Symptom Score (IPSS) and expressed in number. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.
Time frame: 1, 2 , 3 months postoperative
Maximum urine flow rate
Maximum urine flow rate will be assessed by flowmetry and measured by milliliter per second.
Time frame: 1, 2 , 3 months postoperative
Post-void residual volume
Post-void residual volume will be assessed by ultrasound assessment and measured by centimeter cubic.
Time frame: 1, 2 , 3 months postoperative
Bladder contractility evaluation
Bladder contractility will be assessed by urodynamic study. Contractility index is expressed in numbers as follows: strong \> 150, normal 100-150, and weak \< 100.
Time frame: 1, 2 , 3 months postoperative
Bladder detrusor pressure assessment
Bladder detrusor pressure will be assessed by urodynamic study and detrusor pressure measured by CmH2O.
Time frame: 1, 2 , 3 months postoperative
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pyridostigmine
Urinary Bladder, Underactive →